Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Importance Although non–vitamin K antagonist oral anticoagulants (NOACs) are
increasingly used to prevent thromboembolic disease, there are limited data on NOAC …

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines
as the first-line option for the treatment of venous thromboembolism and prevention of stroke …

JAMA Health Forum – Health Policy, Health Care Reform, Health Affairs | JAMA Health Forum |
JAMA Network [Skip to Navigation] Our website uses cookies to enhance your experience. By …

Background Chronic anticoagulation is recommended in patients with hypertrophic
cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral …

Background Great efforts have been made to improve stroke prevention in atrial fibrillation
(AF) patients. Meanwhile, incidence of AF is increasing, which may affect the share of AF …

Ischemic stroke in patients with atrial fibrillation is associated with substantial morbidity and
mortality. The growing epidemic of atrial fibrillation worldwide has raised concerns about the …

Background Mobile health (mHealth) technology is increasingly used in disease
management. Using mHealth tools to integrate and streamline care has improved clinical …

Background Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in
patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral …